vs
Side-by-side financial comparison of SenesTech, Inc. (SNES) and Vir Biotechnology, Inc. (VIR). Click either name above to swap in a different company.
SenesTech, Inc. is the larger business by last-quarter revenue ($421.0K vs $240.0K, roughly 1.8× Vir Biotechnology, Inc.). SenesTech, Inc. runs the higher net margin — -428.5% vs -67975.4%, a 67546.9% gap on every dollar of revenue. On growth, SenesTech, Inc. posted the faster year-over-year revenue change (-16.0% vs -89.9%). SenesTech, Inc. produced more free cash flow last quarter ($-1.7M vs $-167.9M). Over the past eight quarters, SenesTech, Inc.'s revenue compounded faster (0.7% CAGR vs -88.0%).
SenesTech, Inc. is an agricultural biotechnology life-sciences company, specializing in fertility management as a form of pest control. The company's primary product, ContraPest is designed to make brown and black rats infertile. SenesTech is headquartered in Phoenix, Arizona.
Vir Biotechnology, Inc. is a clinical-stage immunology company focused on developing innovative therapies and vaccines to address serious infectious diseases including COVID-19, hepatitis B, HIV, and influenza. It operates primarily in the global biopharmaceutical market, collaborating with leading industry partners to advance its pipeline of targeted immune-based solutions for patient populations worldwide.
SNES vs VIR — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $421.0K | $240.0K |
| Net Profit | $-1.8M | $-163.1M |
| Gross Margin | 55.3% | — |
| Operating Margin | -446.8% | -72267.9% |
| Net Margin | -428.5% | -67975.4% |
| Revenue YoY | -16.0% | -89.9% |
| Net Profit YoY | -43.7% | 23.7% |
| EPS (diluted) | $0.48 | $-1.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $421.0K | — | ||
| Q3 25 | $690.0K | $240.0K | ||
| Q2 25 | $625.0K | $1.2M | ||
| Q1 25 | $485.0K | $3.0M | ||
| Q4 24 | $501.0K | $12.4M | ||
| Q3 24 | $482.0K | $2.4M | ||
| Q2 24 | $459.0K | $3.1M | ||
| Q1 24 | $415.0K | $56.4M |
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-1.3M | $-163.1M | ||
| Q2 25 | $-1.6M | $-111.0M | ||
| Q1 25 | $-1.7M | $-121.0M | ||
| Q4 24 | $-1.3M | — | ||
| Q3 24 | $-1.5M | $-213.7M | ||
| Q2 24 | $-1.6M | $-138.4M | ||
| Q1 24 | $-1.8M | $-65.3M |
| Q4 25 | 55.3% | — | ||
| Q3 25 | 62.8% | — | ||
| Q2 25 | 65.4% | 99.1% | ||
| Q1 25 | 64.5% | — | ||
| Q4 24 | 60.9% | — | ||
| Q3 24 | 65.4% | 97.9% | ||
| Q2 24 | 54.2% | 98.3% | ||
| Q1 24 | 32.5% | 99.9% |
| Q4 25 | -446.8% | — | ||
| Q3 25 | -195.2% | -72267.9% | ||
| Q2 25 | -258.2% | -9754.3% | ||
| Q1 25 | -342.9% | -4602.5% | ||
| Q4 24 | -250.9% | — | ||
| Q3 24 | -321.0% | -9718.7% | ||
| Q2 24 | -349.0% | -5158.7% | ||
| Q1 24 | -444.1% | -142.0% |
| Q4 25 | -428.5% | — | ||
| Q3 25 | -188.1% | -67975.4% | ||
| Q2 25 | -258.6% | -9139.9% | ||
| Q1 25 | -343.3% | -3989.6% | ||
| Q4 24 | -250.5% | — | ||
| Q3 24 | -313.9% | -8979.7% | ||
| Q2 24 | -345.1% | -4500.1% | ||
| Q1 24 | -441.4% | -115.8% |
| Q4 25 | $0.48 | — | ||
| Q3 25 | $-0.28 | $-1.17 | ||
| Q2 25 | $-0.87 | $-0.80 | ||
| Q1 25 | $-1.28 | $-0.88 | ||
| Q4 24 | $-0.15 | — | ||
| Q3 24 | $-2.07 | $-1.56 | ||
| Q2 24 | $-3.08 | $-1.02 | ||
| Q1 24 | $-3.56 | $-0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.6M | $497.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $9.6M | $796.1M |
| Total Assets | $12.8M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.6M | — | ||
| Q3 25 | $10.2M | $497.8M | ||
| Q2 25 | $6.1M | $598.7M | ||
| Q1 25 | $1.7M | $790.9M | ||
| Q4 24 | $1.3M | $901.0M | ||
| Q3 24 | $2.5M | $909.0M | ||
| Q2 24 | $2.0M | $1.1B | ||
| Q1 24 | $3.6M | $1.1B |
| Q4 25 | $9.6M | — | ||
| Q3 25 | $11.3M | $796.1M | ||
| Q2 25 | $7.0M | $947.5M | ||
| Q1 25 | $2.9M | $1.0B | ||
| Q4 24 | $2.5M | $1.2B | ||
| Q3 24 | $3.7M | $1.2B | ||
| Q2 24 | $3.1M | $1.4B | ||
| Q1 24 | $4.6M | $1.5B |
| Q4 25 | $12.8M | — | ||
| Q3 25 | $14.6M | $1.0B | ||
| Q2 25 | $10.4M | $1.2B | ||
| Q1 25 | $3.6M | $1.3B | ||
| Q4 24 | $3.3M | $1.4B | ||
| Q3 24 | $4.4M | $1.5B | ||
| Q2 24 | $4.0M | $1.7B | ||
| Q1 24 | $5.5M | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-167.6M |
| Free Cash FlowOCF − Capex | $-1.7M | $-167.9M |
| FCF MarginFCF / Revenue | -398.3% | -69952.9% |
| Capex IntensityCapex / Revenue | 3.1% | 132.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-5.9M | $-824.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | — | ||
| Q3 25 | $-1.4M | $-167.6M | ||
| Q2 25 | $-1.1M | $-120.2M | ||
| Q1 25 | $-1.6M | $-78.1M | ||
| Q4 24 | $-1.2M | $-446.4M | ||
| Q3 24 | $-1.4M | $-171.5M | ||
| Q2 24 | $-1.6M | $-77.8M | ||
| Q1 24 | $-1.8M | $-109.4M |
| Q4 25 | $-1.7M | — | ||
| Q3 25 | $-1.4M | $-167.9M | ||
| Q2 25 | $-1.2M | $-122.8M | ||
| Q1 25 | $-1.6M | $-79.7M | ||
| Q4 24 | $-1.2M | $-453.7M | ||
| Q3 24 | $-1.4M | $-174.2M | ||
| Q2 24 | $-1.6M | $-78.5M | ||
| Q1 24 | $-1.8M | $-111.3M |
| Q4 25 | -398.3% | — | ||
| Q3 25 | -205.9% | -69952.9% | ||
| Q2 25 | -191.5% | -10111.8% | ||
| Q1 25 | -328.5% | -2630.1% | ||
| Q4 24 | -246.1% | -3666.2% | ||
| Q3 24 | -296.1% | -7321.3% | ||
| Q2 24 | -354.2% | -2553.3% | ||
| Q1 24 | -441.2% | -197.4% |
| Q4 25 | 3.1% | — | ||
| Q3 25 | 6.1% | 132.1% | ||
| Q2 25 | 7.5% | 209.1% | ||
| Q1 25 | 7.4% | 53.7% | ||
| Q4 24 | 3.0% | 59.0% | ||
| Q3 24 | 5.8% | 116.3% | ||
| Q2 24 | 8.5% | 21.7% | ||
| Q1 24 | 0.5% | 3.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
